Sanara Medtech Inc (SMTI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sanara Medtech Inc (SMTI) has a cash flow conversion efficiency ratio of 0.665x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.95 Million) by net assets ($5.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Sanara Medtech Inc to measure how much of total assets are equity-financed.
Sanara Medtech Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Sanara Medtech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Sanara Medtech Inc to evaluate the quality of earnings relative to operating cash generation.
Sanara Medtech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sanara Medtech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Getty Images Holdings Inc.
NYSE:GETY
|
0.067x |
|
CERENO SCIENTIFIC AB B
F:4A1
|
-0.151x |
|
Braemar Hotel & Resorts Inc
NYSE:BHR
|
0.044x |
|
Sula Vineyards Limited
NSE:SULA
|
0.007x |
|
Westwood Holdings Group Inc
NYSE:WHG
|
-0.020x |
|
Petronor E&P Ltd
OL:PNOR
|
-0.047x |
|
Byggma
OL:BMA
|
-0.001x |
|
China ZhengTong Auto Services Holdings Limited
F:ZA0
|
-0.141x |
Annual Cash Flow Conversion Efficiency for Sanara Medtech Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Sanara Medtech Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see Sanara Medtech Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.93 Million | $6.79 Million | 1.145x | +187346.65% |
| 2024-12-31 | $38.91 Million | $-23.78K | -0.001x | +99.16% |
| 2023-12-31 | $44.59 Million | $-3.25 Million | -0.073x | +45.33% |
| 2022-12-31 | $41.72 Million | $-5.55 Million | -0.133x | +16.61% |
| 2021-12-31 | $30.15 Million | $-4.81 Million | -0.160x | +76.89% |
| 2020-12-31 | $5.84 Million | $-4.03 Million | -0.691x | -103.74% |
| 2019-12-31 | $6.39 Million | $-2.17 Million | -0.339x | -236.05% |
| 2018-12-31 | $1.11 Million | $277.14K | 0.249x | +118.27% |
| 2017-12-31 | $102.54K | $-139.86K | -1.364x | -41.01% |
| 2016-12-31 | $-423.07K | $409.25K | -0.967x | -202.23% |
| 2015-12-31 | $-1.27 Million | $-1.20 Million | 0.946x | -53.70% |
| 2014-12-31 | $-825.40K | $-1.69 Million | 2.043x | +176.87% |
| 2013-12-31 | $-2.47 Million | $-1.82 Million | 0.738x | +129.08% |
| 2012-12-31 | $-3.81 Million | $-1.23 Million | 0.322x | +261.94% |
| 2011-12-31 | $-3.86 Million | $-343.60K | 0.089x | +117.11% |
| 2010-12-31 | $2.87 Million | $-1.49 Million | -0.520x | +7.01% |
| 2009-12-31 | $2.31 Million | $-1.30 Million | -0.560x | -116.99% |
| 2008-12-31 | $-321.26K | $-1.06 Million | 3.295x | +1468.87% |
| 2007-12-31 | $-1.81 Million | $-380.90K | 0.210x | -33.10% |
| 2006-12-31 | $-1.27 Million | $-398.97K | 0.314x | -67.45% |
| 2005-12-31 | $-647.47K | $-624.45K | 0.964x | +107.24% |
| 2004-12-31 | $41.20K | $-548.46K | -13.313x | -3955.33% |
| 2001-12-31 | $-2.10 Million | $-723.86K | 0.345x | -16.37% |
| 2000-12-31 | $-1.38 Million | $-569.36K | 0.413x | -75.18% |
| 1999-12-31 | $-377.38K | $-627.86K | 1.664x | -- |
About Sanara Medtech Inc
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and seco… Read more